Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Booster doses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    191 result(s) found for: Booster doses. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000281-15 Sponsor Protocol Number: mRNA-1273-P204 Start Date*: 2023-09-19
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and ...
    Medical condition: Coronavirus Disease 2019
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003768-30 Sponsor Protocol Number: 114778 Start Date*: 2015-03-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, single-blind, randomized, multicenter study to assess the immunogenicity and safety of GSK Biologicals’ dTpa vaccine (Boostrix™) using a new syringe presentation in healthy adolescents ...
    Medical condition: Booster immunization of healthy adolescents against diphtheria, tetanus and pertussis.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002946-11 Sponsor Protocol Number: 111852 Start Date*: 2015-05-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and M...
    Medical condition: Booster immunization of healthy children 4-6 years of age against diphtheria, tetanus, pertussis and polio diseases.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000993-44 Sponsor Protocol Number: CYD63 Start Date*: 2019-06-13
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001249-14 Sponsor Protocol Number: 102547 Start Date*: 2004-10-18
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase III open, multicentre, booster vaccination study to assess the immunogenicity, safety and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type ...
    Medical condition: Booster vaccination against Haemophilus influenzae type b and meningococcal serogroup C diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000924-18 Sponsor Protocol Number: M14P6 Start Date*: 2005-09-07
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vacc...
    Medical condition: Healthy subjects without known medical conditions will be vaccinated against N. menigitidis serogroup C. Active prevention of menigococcal C disease caused by Neisseria menigitidis
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004889-35 Sponsor Protocol Number: UCDCRC/21/10 Start Date*: 2021-12-08
    Sponsor Name:University College Dublin
    Full Title: An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-Co...
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 19 (COVID-19/SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NO (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005366-35 Sponsor Protocol Number: 10-PN-PD-DIT-085 Start Date*: 2013-02-11
    Sponsor Name:BIOVOMED
    Full Title: Evaluation of the immunogenicity and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate v...
    Medical condition: To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in sub...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005367-27 Sponsor Protocol Number: 10-PN-PD-DIT-087 Start Date*: 2013-02-12
    Sponsor Name:BIOVOMED
    Full Title: Evaluation of the immunogenicity and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine (PCV) in children primed with 2 doses of either GSK’s 10-valent PCV or Pfizer’s 13...
    Medical condition: To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 11-12 months of age in s...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004833-17 Sponsor Protocol Number: CBD VP 128/05 Start Date*: 2009-05-01
    Sponsor Name:Dstl
    Full Title: Assessment of the effect of prior anthrax vaccine precipitated (AVP) vaccination on the immune response to booster AVP vaccination.
    Medical condition: Vaccination against potential exposure to anthrax (Bacillus anthracis).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005184-16 Sponsor Protocol Number: IPV26 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Booster Dose of sanofi pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally versus Full Booster Dose of Inactivated Poliomye...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004513-14 Sponsor Protocol Number: 114306 Start Date*: 2015-05-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open-label study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV vaccine (Poliorix) administered as a booster dose at 18 months of age in healthy Chines...
    Medical condition: Booster immunisation of healthy children in the second year of life against poliomyelitis.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005102-30 Sponsor Protocol Number: OVG2011/05 Start Date*: 2011-12-08
    Sponsor Name:University of Oxford
    Full Title: A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vacci...
    Medical condition: The study will include healthy children who have already been vaccinated with 2 doses of Prevenar 13 according to the UK routine immunisation schedule at 2 and 4 months of age. Both vaccines used i...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000645-31 Sponsor Protocol Number: 113264 Start Date*: 2016-06-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, partially double-blind, randomised, controlled, single-centre study to assess the immunogenicity and reactogenicity of three different formulations of GSK Biologicals’ DTPw-HBV-IPV/Hib ...
    Medical condition: Booster immunisation against poliomyelitis disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000596-42 Sponsor Protocol Number: 109621 Start Date*: 2007-10-30
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III open study to assess the safety, reactogenicity and immunogenicity following booster administration of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine, co-ad...
    Medical condition: Booster vaccination against Streptococcus pneumoniae of healthy preterm born children between 16-18 months of age who were previously primed with three doses of GSK Biologicals’10-valent conjugate ...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003279-31 Sponsor Protocol Number: IPV46/EFC13614 Start Date*: 2016-04-19
    Sponsor Name:Sanofi K.K.
    Full Title: Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan (IPV46)
    Medical condition: Poliovirus types 1, 2, and 3
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003324-20 Sponsor Protocol Number: 114386 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open-label study to assess the immune persistence in healthy Chinese toddlers primed in infancy with three doses of GSK Biologicals’ DTPa-IPV/Hib vaccine, and to assess the safety and immunogeni...
    Medical condition: Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-000035-23 Sponsor Protocol Number: VLA2001-307 Start Date*: 2022-04-11
    Sponsor Name:Valneva Austria GmbH
    Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI...
    Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002367-29 Sponsor Protocol Number: ITM202203 Start Date*: 2022-09-29
    Sponsor Name:Instituut van Tropische Geneeskunde Antwerpen
    Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies...
    Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004732-11 Sponsor Protocol Number: Start Date*: 2018-01-19
    Sponsor Name:University of Oxford
    Full Title: Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age
    Medical condition: Meningococcus group B disease, which can cause a variety of symptoms. The most serious of these are meningitis, and septicaemia (also known as blood poisoning).
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:59:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA